Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

An insight into one of NICE’s most long-standing collaborative relationships. For nearly 20 years, NICE has worked with the ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

There is a simple discount patient access scheme for trifluridine–tipiracil. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) is available on the NHS. It is a possible treatment for metastatic colorectal cancer in adults who have had 2 lines of treatment (including ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Venglustat for treating gangliosidoses in people 2 years and over [ID6358]. For information, ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...